Compass Corporate Update, Advancement of New Drug Candidate

 

• Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on track for end of Q1 2025.
• CTX-10726 (a novel PD-1 x VEGF-A bispecific) is advancing as a new drug candidate after a year of preclinical development, with YE 2025 IND expected.
• Two Phase 2 biomarker trials are expected to initiate in mid-2025: tovecimig (in DLL4-positive colorectal cancer) and CTX-471 (in NCAM/CD56 expressing tumors).
• Fully enrolled the third dosing cohort of the Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific) with preliminary data expected in the second half of 2025.
• Estimated $127 million in cash and marketable securities at YE 2024, which is expected to provide cash runway into Q1 2027.

https://www.globenewswire.com/news-release/2025/01/08/3006206/0/en/Compass-Therapeutics-Provides-Corporate-Update-and-Announces-Advancement-of-a-New-Drug-Candidate.html